What is QbDVision?
QbDVision operates as a sophisticated, cloud-native platform engineered to unify knowledge across product and manufacturing processes. By automating critical development workflows, the company addresses the inherent complexities of the product lifecycle journey. Unlike legacy product lifecycle management (PLM) systems, QbDVision offers a purpose-built Digital CMC platform specifically tailored for biopharma organizations. This solution facilitates the transition from R&D to commercial manufacturing by providing real-time, data-driven guidance. The platform is instrumental in streamlining tech transfer and operational workflows, effectively reducing cycle times while maintaining rigorous quality and compliance standards. Its core value proposition lies in its ability to transform fragmented data into actionable insights, thereby empowering teams to accelerate the delivery of life-changing therapies to market.
How much funding has QbDVision raised?
QbDVision has raised a total of $30.3M across 2 funding rounds:
Angel/Seed
$2.3M
Series A
$28M
Angel/Seed (2019): $2.3M, investors not publicly disclosed
Series A (2025): $28M led by Wanxiang Healthcare Investments (WHI), Northpond Ventures, Hudson Park Capital, S3 Ventures, and Create Health Ventures
Key Investors in QbDVision
Wanxiang Healthcare Investments (WHI)
A corporate-backed venture group focusing on digital health and healthcare technologies, targeting early to growth-stage businesses with a long-term investment philosophy.
S3 Ventures
The largest venture capital firm focused on Texas, providing patient and flexible capital to high-impact companies in the healthcare and business technology sectors.
Create Health Ventures
An investment firm dedicated to early-stage digital health businesses, leveraging operational expertise to support B2B software solutions that improve healthcare access and outcomes.
What's next for QbDVision?
Looking ahead, the infusion of capital will likely be directed toward enhancing the platform's core analytical capabilities and expanding its market reach. As the biopharma industry faces increasing pressure to optimize manufacturing efficiency and regulatory adherence, QbDVision is poised to capture significant market share. The company's strategic roadmap involves deepening its integration with existing enterprise systems and potentially exploring new therapeutic verticals. By maintaining a focus on data-driven decision-making and operational excellence, QbDVision is set to redefine the standards of CMC knowledge management. The current funding context suggests a transition toward a more aggressive scaling phase, where the company will likely prioritize talent acquisition and the development of advanced features to support its growing client base of biopharmaceutical innovators.
See full QbDVision company page
